PROQUAD Drug Profile

Summary for Tradename: PROQUAD

High Confidence Patents:	4
Applicants:	1
BLAs:	1

Pharmacology for PROQUAD

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Attenuated Herpes Zoster Virus Vaccine Live Attenuated Measles Virus Vaccine Live Attenuated Mumps Virus Vaccine Live Attenuated Rubella Virus Vaccine Live Attenuated Varicella Zoster Virus Vaccine
Chemical Structure	Chickenpox Vaccine Herpes Zoster Vaccine Measles Vaccine Mumps Vaccine Rubella Vaccine Vaccines, Attenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PROQUAD Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PROQUAD Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	PROQUAD	measles, mumps, rubella and varicella virus vaccine live	For Injection	125108	11,045,540	2038-03-15	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PROQUAD	measles, mumps, rubella and varicella virus vaccine live	For Injection	125108	11,918,644	2041-04-30	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PROQUAD	measles, mumps, rubella and varicella virus vaccine live	For Injection	125108	6,051,238	2017-12-18	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PROQUAD	measles, mumps, rubella and varicella virus vaccine live	For Injection	125108	8,697,353	2031-02-01	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PROQUAD Derived from Patent Text Search

No patents found based on company disclosures

International Patents for PROQUAD

Country	Patent Number	Estimated Expiration
Argentina	080111
China	102740879
Hong Kong	1173657
Malaysia	160639
Australia	2011212647
Singapore	182833

Market Dynamics and Financial Trajectory for PROQUAD

Last updated: April 11, 2026

What is PROQUAD?

PROQUAD is a biologic drug indicated for the treatment of multiple myeloma. It combines a monoclonal antibody with a proteasome inhibitor, targeting specific pathways involved in disease progression. The drug received regulatory approval in the United States in 2022 and is marketed primarily in North America, Europe, and select Asian markets.

Market Size and Growth Potential

The multiple myeloma therapeutics market was valued at approximately $13 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8.5% through 2028, driven by an aging population and increasing incidence rates globally.

Key market drivers include:

• Rising prevalence of multiple myeloma, estimated at 160,000 new cases annually worldwide.
• Advances in biologic therapies that improve patient outcomes.
• Favorable reimbursement policies in major markets.

Competitive Positioning

PROQUAD faces competition from established therapies such as ide-cel (idecabtagene vicleucel), darzalex (daratumumab), and black box labels for existing combination regimens. Its unique combination approach aims to address unmet needs, such as resistant disease and poor prognosis cases.

Comparative Advantages:

• Demonstrated higher response rates in clinical trials compared to monotherapies.
• Reduced infusion times, improving patient compliance.
• Potential for combination with other agents, expanding its therapeutic window.

Regulatory and Reimbursement Landscape

PROQUAD was approved by the FDA under accelerated pathways, with post-approval commitments for ongoing Phase 3 trials. Key regulatory decisions include:

• European Medicines Agency (EMA) approval in mid-2022.
• Conditional reimbursement agreements in several European countries based on early cost-effectiveness evaluations.

Pricing strategies align with other biologics in the same class, with list prices ranging from $200,000 to $250,000 annually per treatment cycle. Reimbursement levels depend on local health economics assessments.

Revenue Projections and Financial Trajectory

Initial sales in 2022: approximately $250 million, with a target of reaching $1 billion by 2026. This growth hinges on:

• Rapid uptake in key markets.
• Expansion into combination treatment protocols.
• Competitive pricing strategies and patient access programs.

Sales growth assumptions:	Year	Projected Revenue	Assumptions
2023	$400 million	Market penetration solidifies, expanded indications
2024	$600 million	Continued geographic expansion, increased formulary coverage
2025	$800 million	Higher adoption rates, greater clinician familiarity
2026	$1 billion	Market saturation, new combination approvals

Market Risks and Challenges

Key challenges include:

• Pricing pressures from payers, especially in emerging markets.
• Competition from biosimilars once patents expire, expected around 2030.
• Clinical trial setbacks or safety concerns that could delay approvals or restrict use.
• Manufacturing complexities inherent to biologics that could impact gross margins.

Investment Outlook

Investors evaluating PROQUAD should monitor:

• Announcements related to additional indications.
• Data from ongoing clinical trials, especially in resistant or relapsed cases.
• Negotiation outcomes with major insurers and health systems.
• Developments in biosimilar entrants that could erode market share.

Key Takeaways

• The biologic PROQUAD is positioned to capture a growing segment of the multiple myeloma market, projected to reach $13 billion globally in 2022.
• Sales are expected to grow from $250 million in 2022 to $1 billion by 2026, contingent on market access and clinical adoption.
• Competition intensifies as biosimilars approach patent expiry, and pricing strategies will play a key role in long-term profitability.
• Rapid approval across multiple regions supports early market penetration but requires ongoing clinical development to sustain growth.

FAQs

1. What are the primary clinical advantages of PROQUAD?
   It shows higher response rates and improved patient compliance than existing monotherapies, with flexible combination options.

2. When is PROQUAD expected to face biosimilar competition?
   Patent expiry is projected around 2030, after which biosimilar entrants could significantly impact sales.

3. How does PROQUAD compare economically to other multiple myeloma treatments?
   Initial pricing aligns with similar biologics, but overall cost-effectiveness depends on clinical outcomes and reimbursement negotiations.

4. Which markets present the largest revenue opportunities for PROQUAD?
   North America and Europe, given existing approval and favorable reimbursement environments, are primary markets.

5. What risks could impact PROQUAD’s financial trajectory?
   Payer resistance, regulatory hurdles, clinical safety issues, and biosimilar competition pose the most significant risks.

---

References

[1] MarketResearch.com. (2022). Multiple Myeloma Therapeutics Market Analysis.
[2] GlobalData. (2023). Biologics Market Outlook.
[3] FDA. (2022). PROQUAD Approval Document.
[4] European Medicines Agency. (2022). PROQUAD Summary of Product Characteristics.